Anmol (Kanotra) Mazariegos

Access decisions are made on evidence — but they’re too often argued on assumption. A trial is read more optimistically than it should be. A comparator is chosen for convenience. A result from one market is quietly imported into another. Each shortcut feels reasonable in the moment, and each one shows up later as an access risk.

I started Assumptions Aside to do the opposite work: set the assumptions aside, look hard at what the evidence actually supports, and rebuild the value case on ground that holds. The result is less comfortable and far more durable — strategy that earns regulatory acceptance and payer value because it was built to withstand scrutiny from the start.

My work spans FDA and EMA alignment, NICE / G-BA / HAS strategy, cost-effectiveness modeling, and evidence-to-policy risk mitigation. What ties it together is a single interest: how development strategy shapes long-term access, pricing sustainability, and public-health impact.